Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

After a joint injury, around 50% of people will go on to develop premature osteoarthritis. Chief investigator Dr Fiona Watt says: “Following the 150 participants in KICK over the next five years will help us to understand why a joint injury leads to osteoarthritis in some individuals, but not others. This will allow us to develop tests which identify those at greatest risk. We hope that this will ultimately enable us to intervene in key pathways following a joint injury to prevent this disabling condition”.

Other work in the Kennedy Institute has identified specific markers of inflammation following injury; KICK aims to determine whether it is possible to predict the development of osteoarthritis from this initial molecular response of the joint to the injury. The study also hopes to identify novel targets for preventing or treating early disease.

KICK is run at The Arthritis Research UK Centre for Osteoarthritis Pathogenesis, based in the Kennedy Institute of Rheumatology, at Oxford, and benefits from a range of collaborations, namely with Andrew Williams, leading UK sports knee surgeon working at Fortius Clinic, London. Commenting on the recent milestone, he said: “This is a great achievement. Understanding the key detrimental humoral 'players' that lead to osteoarthritis will open the possibility of providing therapies to prevent development of osteoarthritis after trauma which is especially prevalent in the young and increasingly so. The need for this is one of the most pressing goals in medicine today.”

KICK is funded by the Kennedy Trust for Rheumatology Research, with additional infrastructure support from Arthritis Research UK.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.